Skip to main content

Table 4 Adhesion to the slipper sole of urinary anticancer drug dropped on the sheet

From: Development and evaluation of adsorption sheet (HD safe sheet-U) using active carbon for the purpose of the preventing the contamination diffusion of urinary excreted anticancer drug

Anticancer drug

Dropping amount (μg)

No sheet

Control

sheet 1

Control

sheet 2

HD safe

Sheet-U

CPA

2000

367.8 ± 16.3

355.3 ± 59.0

256.3 ± 44.3**

ND

IFM

1000

142.4 ± 26.8

32.5 ± 3.3

21.2 ± 2.2***

16.8 ± 2.1*** †

CBDCA

5000

275.2 ± 56.7

16.1 ± 5.0

11.9 ± 3.7

1.5 ± 0.5*** ††

CDDP

100

0.7 ± 0.2

0.3 ± 0.1

0.3 ± 0.1

0.2 ± 0.1*

MTX

6000

1183.1 ± 130.6

78.0 ± 6.4

53.6 ± 7.8***

5.0 ± 1.6*** †††

5-FU

1000

88.1 ± 9.1

5.1 ± 1.3

4.0 ± 0.3

3.8 ± 0.1

Ara-C

1000

137.4 ± 51.5

45.3 ± 15.8

3.1 ± 1.1***

LOQ

GEM

300

45.8 ± 8.5

27.4 ± 5.4

1.5 ± 0.1

LOQ

ADR

1000

198.7 ± 30.9

25.9 ± 3.7

7.7 ± 1.6***

LOQ

Epi-ADR

1000

8.8 ± 0.8

0.7 ± 0.2

0.9 ± 0.2***

0.6 ± 0.2

PTX

200

27.6 ± 9.5

LOQ

LOQ

LOQ

DTX

200

34.2 ± 7.1

2.7 ± 1.8

0.5 ± 0.0*

ND

VP-16

500

118.2 ± 29.5

3.4 ± 1.4

1.5 ± 0.7*

0.6 ± 0.1*

CPT-11

1500

63.9 ± 34.5

LOQ

LOQ

LOQ

  1. The numerical value indicated mean ± standard deviation (μg)(n = 4), **P < 0.01, ***P < 0.001 vs. Control sheet 1, †† P < 0.01, ††† P < 0.001 vs. Control sheet 2 by Fisher’s least significant difference test. LOQ limit of quantitation (Ara-C; <0.5μg, GEM; <0.5μg, ADR;<5.0μg, PTX; <2.5μg, CPT-11; <2.5μg). ND No peak detection